Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Living Cell Technologies
LCT - Living Cell Technologies

News

News updates: Subscribe
Unsubscribe

Archive

June 5, 2008
LCT Expands Diabetes Clinical Trial
>more
June 3, 2008
LCT Lists on International OTCQX
>more
May 21, 2008
LCT interviewed by New Zealand TV program, Close Up
>video
May 12, 2008
LCT presents encapsulation technology at conference
>more
May 8, 2008
LCT features on Channel Ten News
>more
>video
May 8, 2008
LCT prepares to list on international OTCQX
>more
 

News

LCT announces new Chairman and additional independent director
August 25, 2006

Living Cell Technologies Ltd (ASX:LCT) today announced it has accepted the resignation of Mr Michael Yates as Non-Executive Chairman and appointed Mr Simon O'Loughlin as Chairman and Mr Laurie Hunter as an additional independent director.

Mr Yates has advised the Company that he will today resign as Chairman and Director due to work commitments in the UK and his extensive travelling requirements.

Related Document
Download ( = 41Kb )

LCT - Living Cell Technologies

Q & A

What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors. >more
 
HomeContactSitemapLegalsPrivacy
  
graphic design and website design - PDF Communications Ltd